Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection
AG-221-AML-005
Phase 2 small_molecule active
Quick answer
Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active